|
Reduction of tumor growth using immune checkpoint inhibitors
Abstract
Researchers at USC have generated antibodies which enhance adaptive anti-tumor immune response by eliciting innate immunity. The antibodies are conjugated to CpG, a Toll-like receptor 9 agonist, which activates innate immune cells. Preclinical studies showed that CpG-conjugated...
|